New combo aims to boost CAR T-Cell therapy for rare lymphoma
NCT ID NCT05934448
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard CAR T-cell therapy can improve outcomes for people with relapsed or refractory primary mediastinal B-cell lymphoma. About 35 participants will receive pembrolizumab before and after CAR T-cell infusion. The main goal is to see how many achieve a complete response at 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) and CAR T-cell therapy (axicabtagene-ciloleucel or lisocabtagene maraleucel)
- What this could lead to
- If successful, this combination could improve the chance of complete remission for patients with hard-to-treat primary mediastinal B-cell lymphoma.
- What could go wrong
- This is a small, early-phase trial (35 people) with no control group, so results may not apply broadly. The combination also carries risks of serious side effects like cytokine release syndrome and nerve toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- New drug combo aims to tame aggressive lymphoma in frail patients
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells take aim at Tough-to-Treat blood cancers